Impact of glutathione S transferases P1 (Ile105Val) variants on the risk of GSTp, phosphorylated c-Jun kinase, and P53 phenotypic expression and their implications on overall survival outcomes in non-small cell lung cancer patients treated with chemotherapy

基因型 GSTP1公司 基因分型 生物 相关性 表型 内科学 分子生物学 医学 基因 遗传学 几何学 数学
作者
Anurag Pathak,Nuzhat Husain,Saumya Shukla,Rahul Pandey,Surya Kant,Lakshmi Bala
出处
期刊:Mutation Research: Fundamental And Molecular Mechanisms Of Mutagenesis [Elsevier BV]
卷期号:824: 111775-111775 被引量:2
标识
DOI:10.1016/j.mrfmmm.2022.111775
摘要

This study focused on GST-M1, T1 null, and P1 Ile105Val variant genotypes associated with the risk of altered expression of GSTp, pJNK, and P53 in NSCLC patients. These markers and overall survival (OS) were correlated with a key set of clinicopathological characteristics.Genotyping of GST- M1, T1 (+/-), and P1 (Ile105Val) was performed using PCR-RFLP.The expression of GSTp, pJNK, and P53 phenotypes was assessed by immunohistochemistry. The Spearman test was used to examine the correlation between GSTp, pJNK, and P53. Kaplan-Meier test was used for OS analysis.GSTP1 Val/Val and Ile/Val genotypes notably increased GSTp expression by 1.8 and 1.7 fold, respectively (p = 0.04,p = 0.06). GSTP1 Val/Val and Ile/Val genotypes considerably reduced P53 expression by 0.61 and 0.57 fold, respectively (p = 0.03& p = 0.05), respectively. GSTp, pJNK, and P53 were significantly co-expressed (p < 0.001). GSTp and pJNK expression showed a moderate negative correlation (ρ = -0.32, p = 0.046). In contrast, GSTp and P53 expression exhibited a strong negative correlation (ρ = -0.53, p < 0.0001). There was no correlation between P53 and pJNK expression(ρ = 0.07, p = 0.54). The patient's median OS was 8.9 months, and it was significantly related to pack-years, stage, metastasis, and GSTM1(-/-) genotypes (p > 0.05). SQCLC showed poor OS than ADC (5.7 months vs.9.1 months, p = 0.2). Stage IV and metastasis significantly reduced the OS (p = 0.001). The tumour size and lymph nodes reflected poor OS (p = 0.07&p = 0.06). Gemcitabine+Cisplatin and Gefitinib showed a slightly higher rate of survival (9.3 months and 8.1 months) than Pemtrexe+Cisplatin treatment (7.0 months,p = 0.8). Multivariate analysis revealed that pack-years and GSTp were independent predictors for OS (p = 0.03).GSTp, pJNK, and P53 showed interconnected cascading. Age, pack-year, stage, and GSTp were found to be significant predictive factors for OS.Pack-years, GSTp independent OS predictor.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
张姣姣完成签到,获得积分10
1秒前
yannick发布了新的文献求助10
1秒前
动听绿凝发布了新的文献求助10
1秒前
袁志振发布了新的文献求助10
3秒前
goodltl完成签到 ,获得积分10
3秒前
Lig完成签到,获得积分10
3秒前
咿呀呀完成签到,获得积分10
4秒前
吃面的章鱼完成签到,获得积分10
4秒前
4秒前
郁赹完成签到,获得积分10
5秒前
ybyb发布了新的文献求助10
5秒前
5秒前
我爱陶子完成签到 ,获得积分10
6秒前
6秒前
ZixuanZhang发布了新的文献求助10
7秒前
hhcai发布了新的文献求助10
8秒前
积极的糖豆完成签到 ,获得积分10
9秒前
槑槑不好玩完成签到 ,获得积分10
10秒前
葵魁发布了新的文献求助10
10秒前
QQ发布了新的文献求助10
10秒前
mr_beard完成签到 ,获得积分10
10秒前
11秒前
WangSiwei完成签到,获得积分10
11秒前
lihaichuan完成签到,获得积分10
11秒前
shinen完成签到,获得积分10
11秒前
12秒前
赘婿应助小样采纳,获得10
13秒前
所所应助许砚采纳,获得10
14秒前
小黑之家完成签到,获得积分10
15秒前
16秒前
平淡夜柳发布了新的文献求助30
16秒前
16秒前
wen完成签到,获得积分10
17秒前
完美世界应助QQ采纳,获得10
17秒前
okiya发布了新的文献求助10
18秒前
常尽欢完成签到 ,获得积分10
19秒前
子车半烟完成签到,获得积分10
19秒前
zt完成签到,获得积分10
19秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
FUNDAMENTAL STUDY OF ADAPTIVE CONTROL SYSTEMS 500
微纳米加工技术及其应用 500
Nanoelectronics and Information Technology: Advanced Electronic Materials and Novel Devices 500
Performance optimization of advanced vapor compression systems working with low-GWP refrigerants using numerical and experimental methods 500
Constitutional and Administrative Law 500
PARLOC2001: The update of loss containment data for offshore pipelines 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5294873
求助须知:如何正确求助?哪些是违规求助? 4444563
关于积分的说明 13833824
捐赠科研通 4328729
什么是DOI,文献DOI怎么找? 2376305
邀请新用户注册赠送积分活动 1371655
关于科研通互助平台的介绍 1336835